Glycemic and psychosocial outcomes of automated insulin delivery in older and high-risk populations with type 1 diabetes: a systematic review and meta-analysis.
Puguh Oktavian, Citrawati Dyah Kencono Wungu, Indah Mohd Amin, Sony Wibisono Mudjanarko
{"title":"Glycemic and psychosocial outcomes of automated insulin delivery in older and high-risk populations with type 1 diabetes: a systematic review and meta-analysis.","authors":"Puguh Oktavian, Citrawati Dyah Kencono Wungu, Indah Mohd Amin, Sony Wibisono Mudjanarko","doi":"10.1210/clinem/dgag344","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Automated insulin delivery (AID) has revolutionized care for people with type 1 diabetes. However, its efficacy and safety in older adults (≥60 years) and high-risk populations, including those with impaired awareness of hypoglycemia, or cognitive or functional impairment, have not been systematically evaluated.</p><p><strong>Materials and methods: </strong>CENTRAL, PubMed, Web of Science, Scopus, and ClinicalTrials.gov from inception to March 10, 2026. Studies on automated insulin delivery in older and high-risk individuals with type 1 diabetes were included. The primary outcome was time in range (3.9-10.0 mmol/L [70-180 mg/dL]). Secondary outcomes included time above range, time below range, psychosocial well-being (Gold, Clarke, and Hypoglycemia Fear Survey score), and serious adverse events. Pooled effect sizes were estimated with random-effects models (PROSPERO, CRD420251273526).</p><p><strong>Results: </strong>Twenty-three studies involving 967 participants (11 randomized controlled trials, 3 single-arm, and 9 cohort studies) were included. Automated insulin delivery increased time in range by 11.38% (95% CI: 8.07-14.70; I2 = 70%; P < .0001; very low certainty; equivalent to 2.7 hours/day). Time in range improvement was observed during the day (8.70%; 95% CI 5.18-12.22%) and overnight (13.35%; 95% CI 11.07-15.62%). Favorable improvement was also comparable among commercial and noncommercial systems. Automated insulin delivery reduced the time spent in hyperglycemia (-7.89%) and hypoglycemia (-1.16%). No significant differences in psychosocial well-being were observed. Diabetic ketoacidosis and severe hypoglycemia events were not significant.</p><p><strong>Conclusion: </strong>Automated insulin delivery exhibits favorable glycemic outcomes and safety profiles in older and high-risk individuals with type 1 diabetes, suggesting potential benefits for populations traditionally considered vulnerable, although no significant improvements were observed in psychosocial outcomes.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of clinical endocrinology and metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/clinem/dgag344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Automated insulin delivery (AID) has revolutionized care for people with type 1 diabetes. However, its efficacy and safety in older adults (≥60 years) and high-risk populations, including those with impaired awareness of hypoglycemia, or cognitive or functional impairment, have not been systematically evaluated.
Materials and methods: CENTRAL, PubMed, Web of Science, Scopus, and ClinicalTrials.gov from inception to March 10, 2026. Studies on automated insulin delivery in older and high-risk individuals with type 1 diabetes were included. The primary outcome was time in range (3.9-10.0 mmol/L [70-180 mg/dL]). Secondary outcomes included time above range, time below range, psychosocial well-being (Gold, Clarke, and Hypoglycemia Fear Survey score), and serious adverse events. Pooled effect sizes were estimated with random-effects models (PROSPERO, CRD420251273526).
Results: Twenty-three studies involving 967 participants (11 randomized controlled trials, 3 single-arm, and 9 cohort studies) were included. Automated insulin delivery increased time in range by 11.38% (95% CI: 8.07-14.70; I2 = 70%; P < .0001; very low certainty; equivalent to 2.7 hours/day). Time in range improvement was observed during the day (8.70%; 95% CI 5.18-12.22%) and overnight (13.35%; 95% CI 11.07-15.62%). Favorable improvement was also comparable among commercial and noncommercial systems. Automated insulin delivery reduced the time spent in hyperglycemia (-7.89%) and hypoglycemia (-1.16%). No significant differences in psychosocial well-being were observed. Diabetic ketoacidosis and severe hypoglycemia events were not significant.
Conclusion: Automated insulin delivery exhibits favorable glycemic outcomes and safety profiles in older and high-risk individuals with type 1 diabetes, suggesting potential benefits for populations traditionally considered vulnerable, although no significant improvements were observed in psychosocial outcomes.
背景:自动化胰岛素输送(AID)已经彻底改变了1型糖尿病患者的护理。然而,其在老年人(≥60岁)和高危人群(包括低血糖意识受损、认知或功能障碍的人群)中的有效性和安全性尚未得到系统评估。材料和方法:CENTRAL, PubMed, Web of Science, Scopus和ClinicalTrials.gov,从成立到2026年3月10日。研究对象包括老年人和高危1型糖尿病患者的自动胰岛素输送。主要终点是时间范围(3.9-10.0 mmol/L [70-180 mg/dL])。次要结局包括高于范围的时间、低于范围的时间、社会心理健康(Gold、Clarke和低血糖恐惧调查得分)和严重不良事件。用随机效应模型估计合并效应大小(PROSPERO, CRD420251273526)。结果:纳入23项研究,涉及967名受试者(11项随机对照试验,3项单臂研究,9项队列研究)。自动化胰岛素递送使范围内的时间增加了11.38% (95% CI: 8.07-14.70; I2 = 70%; P < 0.0001;非常低的确定性;相当于2.7小时/天)。在白天(8.70%;95% CI 5.18-12.22%)和夜间(13.35%;95% CI 11.07-15.62%)观察到范围内时间改善。有利的改善在商业和非商业系统之间也具有可比性。自动胰岛素输送减少了高血糖(-7.89%)和低血糖(-1.16%)的时间。在心理健康方面没有观察到显著差异。糖尿病酮症酸中毒和严重低血糖事件无显著性。结论:自动化胰岛素输送在老年和高风险的1型糖尿病患者中显示出良好的血糖结局和安全性,这表明传统上被认为是弱势群体的潜在益处,尽管在社会心理结局方面没有观察到显著的改善。